-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk To Advance Subcutaneous And Oral Amycretin For Weight Management Into Phase 3 Clinical Development

Benzinga·06/12/2025 17:13:30
Listen to the news